Merrill keeps Millennium at neutral

Millennium Pharmaceuticals, Inc. was maintained by Merrill Lynch analyst Tom McGahren at neutral on mixed Velcade data presented at the American Society for Clinical Oncology. The phase 2 trial studied Velcade in combination with standard chemo therapy in non-small cell lung cancer. Shares of the Cambridge, Mass.-based pharmaceutical company were down $0.07, or 0.81%, at $8.60 on volume of 6,552,267 shares versus the three-month running average of 4,015,860 shares. (Nasdaq: MLNM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.